IL2 and systemic lupus erythematosus: Disease activity and serum IL-2 of SLE patients were determined before and after receiving UC-MSCs.<h4>Results</h4>Both UC-MSCs and IL-2 improved lupus symptoms in lupus-prone mice 1 week after treatment, while the effects of UC-MSCs lasted up to 4 weeks.